Abstract
Respiratory failure and systemic inflammation are paramount features of severe SARS-CoV-2 disease (COVID-19). Extracorporeal membrane oxygenation (ECMO) therapy has a potential role in patients with refractory disease. An inflammatory response due to blood contact with hemofilters, functioning as a synergic inflammatory stimulus, can lead to a hyperinflammatory state, relatable to cytokine release syndromes. After the first patient succumbed to a refractory vasodilatory shock believed to be due to hyperinflammatory state, a strategy of blood purification through cytokine adsorption therapy (CAT) with CytoSorb® was designed. In this case series, the authors describe the initial experience with such strategy. CAT was employed with no direct complications and helped controlling the inflammatory state, with all patients halting vasopressor support in 72 h and biomarker levels (C-reactive protein, ferritin, and interleukin-6) showing negative trends in most patients. Analysis of inflammatory biomarkers evolution highlighted 2 biomarker profiles related to the presence or absence of superinfection at the time of CAT implementation. In this case series of severe COVID-19 patients, 3 patients died – irreversible lung fibrosis, complications of critical hypoxemia before ECMO induction and complications of systemic anticoagulation were the causes. This case series aimed to contribute to the body of evidence substantiating CAT utilization in hyperinflammatory patients, namely, COVID-19 patients requiring ECMO rescue.
References
1.
Tay
MZ
, Poh
CM
, Rénia
L
, MacAry
PA
, Ng
LFP
. The trinity of COVID-19: immunity, inflammation and intervention
. Nat Rev Immunol
. 2020
;20
(6
):363
–74.
2.
Xu
Z
, Shi
L
, Wang
Y
, Zhang
J
, Huang
L
, Zhang
C
, Pathological findings of COVID-19 associated with acute respiratory distress syndrome
. Lancet Respir Med
. 2020 Apr
;8
(4
):420
–2
. .3.
Henderson
LA
, Canna
SW
, Schulert
GS
, Volpi
S
, Lee
PY
, Kernan
KF
, On the alert for cytokine storm: immunopathology in COVID-19
. Arthritis Rheumatol
. 2020 Jul 10
;72
(7
):1059
–63
.4.
Gu
J
, Gong
E
, Zhang
B
, Zheng
J
, Gao
Z
, Zhong
Y
, Multiple organ infection and the pathogenesis of SARS
. J Exp Med
. 2005
;202
(3
):415
–24
. .5.
Mehta
P
, McAuley
DF
, Brown
M
, Sanchez
E
, Tattersall
RS
, Manson
JJ
. COVID-19: consider cytokine storm syndromes and immunosuppression
. Lancet
. 2020
;395
(10229
):1033
–4
. .6.
Becker
RC
. COVID-19 update: covid-19-associated coagulopathy
. J Thromb Thrombolysis
. 2020
;50
(1
):54
–67
. .7.
Thachil
J
, Tang
N
, Gando
S
, Falanga
A
, Cattaneo
M
, Levi
M
, ISTH interim guidance on recognition and management of coagulopathy in COVID-19
. J Thromb Haemost
. 2020
;18
(5
):1023
–6
. .8.
Tang
X
, Du
RH
, Wang
R
, Cao
TZ
, Guan
LL
, Yang
CQ
, Comparison of hospitalized patients with ARDS caused by COVID-19 and H1N1
. Chest
. 2020
;158
(1
):195
–205
. .9.
WHO. No Title. International Clinical Trials Registry Platform. [Online].
10.
Ruan
Q
, Yang
K
, Wang
W
, Jiang
L
, Song
J
. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China
. Intensive Care Med
. 2020
;46
(5
):846
–8
. .11.
Zhou
F
, Yu
T
, Du
R
, Fan
G
, Liu
Y
, Liu
Z
, Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study
. Lancet
. 2020
;395
(10229
):1054
–62
.12.
Grasselli
G
, Pesenti
A
, Cecconi
M
. Critical care utilization for the COVID-19 outbreak in Lombardy, Italy
. JAMA
. 2020 Apr 28
;323
(16
):1545
–6
.13.
Huang
C
, Wang
Y
, Li
X
, Ren
L
, Zhao
J
, Hu
Y
, Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China
. Lancet
. 2020 Feb
;395
(10223
):497
–506
.14.
Zhang
B
, Zhou
X
, Qiu
Y
, Song
Y
, Feng
F
, Feng
J
, Clinical characteristics of 82 cases of death from COVID-19
. PLoS One
. 2020
;15
(7
):e0235458
. .15.
Kowalewski
M
, Fina
D
, Słomka
A
, Raffa
GM
, Martucci
G
, Lo Coco
V
, COVID-19 and ECMO: the interplay between coagulation and inflammation – a narrative review
. Crit Care
. 2020
;24
(1
):1
–10
.16.
Li
M
, Gu
SC
, Wu
XJ
, Xia
JG
, Zhang
Y
, Zhan
QY
. Extracorporeal membrane oxygenation support in 2019 novel coronavirus disease: indications, timing, and implementation
. Chin Med J
. 2020 May
;133
(9
):1115
–7
. .17.
Ramanathan
K
, Antognini
D
, Combes
A
, Paden
M
, Zakhary
B
, Ogino
M
, Planning and provision of ECMO services for severe ARDS during the COVID-19 pandemic and other outbreaks of emerging infectious diseases
. Lancet Respir Med
. 2020
;8
(5
):518
–26
. .18.
Burrell
AJC
, Lubnow
M
, Enger
TB
, Nanjayya
VB
, Philipp
A
, Malfertheiner
MV
, The impact of venovenous extracorporeal membrane oxygenation on cytokine levels in patients with severe acute respiratory distress syndrome: a prospective, observational study
. Crit Care Resusc
. 2017 Oct
;19
(Suppl 1
):37
–44
.19.
Al-Fares
A
, Pettenuzzo
T
, Del Sorbo
L
. Extracorporeal life support and systemic inflammation
. Intensive Care Med Exp
. 2019
;7
(Suppl 1
):46
–14
. .20.
Landis
RC
, Brown
JR
, Fitzgerald
D
, Likosky
DS
, Shore-Lesserson
L
, Baker
RA
, Attenuating the systemic inflammatory response to adult cardiopulmonary bypass: a critical review of the evidence base
. J Extra Corpor Technol
. 2014 Sep
;46
(3
):197
–211
.21.
RECOVERY Collaborative Group
; Horby
P
, Lim
WS
, Emberson
JR
, Mafham
M
, Bell
JL
, Dexamethasone in hospitalized patients with covid-19 – preliminary report
. N Engl J Med
. 2021 Feb 25
;384
(8
):693
–704
.22.
Angus
DC
, van der Poll
T
. Severe sepsis and septic shock
. N Engl J Med
. 2013 Aug 29
;369
(9
):2063
–51
. .23.
Ronco
C
, Reis
T
, De Rosa
S
. Coronavirus epidemic and extracorporeal therapies in intensive care: si vis pacem para bellum
. Blood Purif
. 2020
;49
(3
):255
–8
. .24.
Akil
A
, Ziegeler
S
, Reichelt
J
, Rehers
S
, Abdalla
O
, Semik
M
, Combined use of cytosorb and ECMO in patients with severe pneumogenic sepsis
. Thorac Cardiovasc Surg
. 2021 Apr
;69
(3
):246
–51
.25.
CytoSorbents
. CytoSorb therapy indications and set-up [Internet]
. 2016
. Available from: http://cytosorb-therapy.com/wp-content/uploads/2016/03/CytoSorb_Booklet_EN_1.0.pdf.26.
Scheier
J
, Humbert
V
; CytoSorbents
. Options for actions regarding the use of CytoSorb therapy in COVID-19 patients (Status April 8th 2020)
. 2020
. p. 1
–5
.27.
Kogelmann
K
, Jarczak
D
, Scheller
M
, Drüner
M
. Hemoadsorption by cytosorb in septic patients: a case series
. Crit Care
. 2017
;21
(1
):74
–10
. .28.
Leisman
DE
, Ronner
L
, Pinotti
R
, Taylor
MD
, Sinha
P
, Calfee
CS
, Cytokine elevation in severe and critical COVID-19: a rapid systematic review, meta-analysis, and comparison with other inflammatory syndromes
. Lancet Respir Med
. 2020 Dec
;8
(12
):1233
–44
. .29.
Träger
K
, Fritzler
D
, Fischer
G
, Schröder
J
, Skrabal
C
, Liebold
A
, Treatment of post-cardiopulmonary bypass SIRS by hemoadsorption: a case series
. Int J Artif Organs
. 2016 Mar 25
;39
(3
):141
–6
. .30.
Chen
X
, Zhao
B
, Qu
Y
, Chen
Y
, Xiong
J
, Feng
Y
, Detectable serum severe acute respiratory syndrome coronavirus 2 viral load (RNAemia) is closely correlated with drastically elevated interleukin 6 level in critically ill patients with coronavirus disease 2019
. Clin Infect Dis
. 2020 Nov 5
;71
(8
):1937
–42
.31.
Poston
JT
, Patel
BK
, Davis
AM
. Management of critically ill adults with COVID-19
. JAMA
. 2020
;323
(18
):1839
–41
. .32.
Berlot
G
, Pintacuda
S
, Moro
E
, Paluzzano
G
, Scamperle
A
, Chillemi
A
, Effects of tocilizumab versus hemoadsorption combined with tocilizumab in patients with SARS-CoV-2 pneumonia: preliminary results
. Int J Artif Organs
. 2021 Feb 11
;39139882198933
. .33.
Toniati
P
, Piva
S
, Cattalini
M
, Garrafa
E
, Regola
F
, Castelli
F
, Tocilizumab for the treatment of severe COVID-19 pneumonia with hyperinflammatory syndrome and acute respiratory failure: a single center study of 100 patients in Brescia, Italy
. Autoimmun Rev
. 2020 Jul
;19
(7
):102568
.© 2021 S. Karger AG, Basel
2021
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.
